19.65
Schlusskurs vom Vortag:
$20.06
Offen:
$19.89
24-Stunden-Volumen:
884.48K
Relative Volume:
2.16
Marktkapitalisierung:
$1.06B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.21M
KGV:
-10.40
EPS:
-1.89
Netto-Cashflow:
$-68.53M
1W Leistung:
-7.14%
1M Leistung:
+10.58%
6M Leistung:
-12.67%
1J Leistung:
-13.44%
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Vergleichen Sie ELVN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ELVN
Enliven Therapeutics Inc
|
19.65 | 1.06B | 0 | -85.21M | -68.53M | -1.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-16 | Eingeleitet | Goldman | Buy |
2024-12-13 | Eingeleitet | BTIG Research | Buy |
2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
2024-04-09 | Eingeleitet | Mizuho | Buy |
2023-03-29 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Enliven Therapeutics CEO Kintz sells $277k in shares By Investing.com - Investing.com India
Enliven grosses $230M from stock sale - BizWest
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Eastern Progress
Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data - MSN
Enliven Raises $230m To Fund Scemblix Leukemia Challenger - insights.citeline.com
Enliven Therapeutics (NASDAQ:ELVN) Given New $52.00 Price Target at Robert W. Baird - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at The Goldman Sachs Group - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up on Analyst Upgrade - Defense World
10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey
Enliven Therapeutics Closes Public Offering - MarketScreener
Biotech Enliven Therapeutics Secures Massive $230M Funding Through Oversubscribed Public Offering - Stock Titan
Form 424B5 Enliven Therapeutics, - StreetInsider
Enliven (ELVN) Gains Buy Rating from Goldman Sachs with $37 Price Target | ELVN Stock News - GuruFocus
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down – Should You Sell? - Defense World
Enliven (ELVN) Initiates $200M Public Stock Offering | ELVN Stoc - GuruFocus
Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - The Malaysian Reserve
Enliven Therapeutics prices $200 million public offering By Investing.com - Investing.com South Africa
Enliven Therapeutics Inc (ELVN) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Enliven to sell $200M in stock after positive drug trial - BizWest
Enliven Therapeutics Announces $200 Mln Offering Of Common Stock, Pre-Funded Warrants - Nasdaq
Enliven Therapeutics prices $200 million public offering - Investing.com
Biotech Breakthrough: Enliven Therapeutics Secures Massive $200M Funding Backed by Goldman Sachs - Stock Titan
Enliven Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com
Enliven Therapeutics Announces Public Offering Of $200 Mln Of Shares - Nasdaq
Enliven Therapeutics Launches $200 Million Securities Offering - marketscreener.com
Enliven Therapeutics Announces Positive Phase 1 Trial Results - TipRanks
Enliven Therapeutics announces $200 million public offering - Investing.com
SEC Form 424B5 filed by Enliven Therapeutics Inc. - Quantisnow
Biotech Enliven Therapeutics Unveils Massive $200M Stock Offering with Pre-Funded Warrants Option - Stock Titan
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress - PR Newswire
California State Teachers Retirement System Buys 1,940 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $984,000 Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Two Sigma Investments LP Has $329,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Bank of America Corp DE Sells 14,504 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4% After Insider Selling - Defense World
Millennium Management LLC Buys 26,449 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
ELVN Stock Price and Chart — NASDAQ:ELVN - TradingView
Ameriprise Financial Inc. Invests $789,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
What is Lifesci Capital’s Forecast for ELVN FY2025 Earnings? - Defense World
(ELVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
BNP Paribas Financial Markets Purchases New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
What is Lifesci Capital’s Forecast for ELVN Q2 Earnings? - Defense World
Enliven Therapeutics (ELVN) Gets a Buy from Mizuho Securities - The Globe and Mail
Mizuho Adjusts Price Target on Enliven Therapeutics to $41 From $39, Maintains Outperform Rating - marketscreener.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Increased by Deutsche Bank AG - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $37.25 Consensus PT from Analysts - Defense World
Enliven Therapeutics to Present at Upcoming Investor Conferences - Nasdaq
(ELVN) Proactive Strategies - news.stocktradersdaily.com
Enliven Therapeutics chief scientific officer sells $81,533 in stock - Investing.com Australia
Enliven Therapeutics chief scientific officer sells $81,533 in stock By Investing.com - Investing.com India
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Enliven Therapeutics Inc-Aktie (ELVN) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Jun 20 '25 |
Sale |
21.40 |
12,500 |
267,458 |
965,188 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):